Brainstorm Cell Therapeutics Stock Today
| BCLI Stock | USD 1.82 0.01 0.55% |
Performance3 of 100
| Odds Of DistressOver 85
|
Brainstorm Cell is trading at 1.82 as of the 1st of February 2025. This is a 0.55 percent decrease since the beginning of the trading day. The stock's open price was 1.8299. Brainstorm Cell has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 5th of August 2024 and ending today, the 1st of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of August 2003 | Category Healthcare | Classification Health Care |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. The company has 5.7 M outstanding shares of which 172.99 K shares are currently shorted by private and institutional investors with about 1.25 trading days to cover. More on Brainstorm Cell Therapeutics
Moving against Brainstorm Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Brainstorm Stock Highlights
| President CoCEO | Chaim Lebovits | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBrainstorm Cell can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Brainstorm Cell's financial leverage. It provides some insight into what part of Brainstorm Cell's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brainstorm Cell Therapeutics (BCLI) is traded on NASDAQ Exchange in USA. It is located in 1325 Avenue of Americas, New York, NY, United States, 10019 and employs 29 people. Brainstorm Cell is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.89 M. Brainstorm Cell Ther conducts business under Biotechnology sector and is part of Health Care industry. The entity has 5.7 M outstanding shares of which 172.99 K shares are currently shorted by private and institutional investors with about 1.25 trading days to cover.
Brainstorm Cell Therapeutics currently holds about 12.24 M in cash with (20.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34.
Check Brainstorm Cell Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Brainstorm Cell Ther is $10.89 Million. Brainstorm Cell Therapeutics shows 9.0 percent of its outstanding shares held by insiders and 13.89 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Brainstorm Ownership Details
Brainstorm Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Securities, Llc | 2024-06-30 | 102 K | |
| Tower Research Capital Llc | 2024-06-30 | 86.6 K | |
| Group One Trading, Lp | 2024-06-30 | 46.8 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 37 K | |
| Wells Fargo & Co | 2024-06-30 | 28.8 K | |
| Creative Planning Inc | 2024-06-30 | 20.9 K | |
| Janney Montgomery Scott Llc | 2024-06-30 | 20.5 K | |
| Saxony Capital Management Llc | 2024-06-30 | 12.9 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 12 K | |
| Armistice Capital, Llc | 2024-06-30 | 7.9 M | |
| Vanguard Group Inc | 2024-06-30 | 1.5 M |
Brainstorm Cell Historical Income Statement
Brainstorm Stock Against Markets
Brainstorm Cell Corporate Management
| Antal PearlLendner | VP Counsel | Profile | |
| Daniel Offen | Chief Advisor | Profile | |
| Ibrahim MD | Executive Officer | Profile | |
| Mary Turner | Senior Affairs | Profile | |
| Netta BlondheimShraga | Senior Development | Profile | |
| Stacy Lindborg | CoChief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brainstorm Cell. If investors know Brainstorm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brainstorm Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Brainstorm Cell Ther is measured differently than its book value, which is the value of Brainstorm that is recorded on the company's balance sheet. Investors also form their own opinion of Brainstorm Cell's value that differs from its market value or its book value, called intrinsic value, which is Brainstorm Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brainstorm Cell's market value can be influenced by many factors that don't directly affect Brainstorm Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brainstorm Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Brainstorm Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brainstorm Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.